Inclusion Criteria: 

• Able to understand and comply with study procedures, understand the risks involved, and provide written informed consent. 
• For Phase 1, histologically and / or cytological confirmed locally advanced, recurrent or relapsed or metastatic incurable solid malignancy.
• For Phase 2, four cohorts will be enrolled:
  • Cohort A: EXON 14 NSCLC (c-Met naïve);
  • Cohort B: EXON 14 NSCLC (c-Met experienced; progressed on prior c-Met inhibitor);
  • Cohort C: basket of tumor types with c-Met high amplification;
  • Cohort D: basket of tumor types with c-Met fusions. 
• Local/archival result (tissue and/or plasma) of a positive c-Met dysregulation is required.
• Measurable disease according to RECIST v1.1. 
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
• No planned major surgery within 4 weeks of first dose of APL-101.

 Exclusion Criteria:

• Hypersensitivity to APL-101, excipients of the drug product, or other components of the study treatment regimen. 
• Known mutation/gene rearrangement of EGFR, ALK, ROS1, RET, NTRK, KRAS, BRAF or other driver mutation/gene rearrangement apart from MET.
• History of, or at risk for, cardiac disease (e.g., long QT syndrome [> 450 msec QTcF or concurrent treatment with any medication that prolongs QT interval). 
• Unable to swallow orally administered medication whole. 
• Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter drug absorption (e.g., Crohn's, ulcerative colitis, active inflammatory bowel disease, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome).
• Women who are breastfeeding.